WAI CHUN BIO-TECHNOLOGY LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.11 HKD | -3.51% |
|
+10.00% | -23.61% |
| 01/04 | Wai Chun Bio-Technology Limited Announces Change of Independent Non-Executive Director | CI |
| 28/03 | Wai Chun Bio-Technology Limited Announces Company Secretary Changes | CI |
Valuation
| Fiscal Period: June | 2018 | 2019 | 2020 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 1,095 | 746.6 | 481.1 | 67.23 | 17.49 |
| Enterprise Value (EV) 1 | 1,187 | 840.4 | 605.5 | 211 | 145.5 |
| P/E ratio | -20.4 x | -236 x | -59 x | -4.67 x | -1.12 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 2.28 x | 1.29 x | 0.85 x | 0.1 x | 0.02 x |
| EV / Revenue | 2.47 x | 1.45 x | 1.07 x | 0.31 x | 0.19 x |
| EV / EBITDA | -26.3 x | 41.1 x | 31.8 x | 8.63 x | 6.79 x |
| EV / FCF | 145 x | -141 x | -16.3 x | - | 18.8 x |
| FCF Yield | 0.69% | -0.71% | -6.15% | - | 5.33% |
| Price to Book | -23 x | -14.7 x | -12.7 x | -1.78 x | -0.5 x |
| Nbr of stocks (in thousands) | 1,65,907 | 1,65,907 | 1,65,907 | 1,68,076 | 1,71,476 |
| Reference price 2 | 6.600 | 4.500 | 2.900 | 0.4000 | 0.1020 |
| Announcement Date | 29/04/19 | 16/07/20 | 24/05/21 | 28/11/22 | 30/10/23 |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2018 | 2019 | 2020 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales 1 | 480.9 | 579.2 | 567.6 | 671.5 | 773.7 |
| EBITDA 1 | -45.17 | 20.44 | 19.07 | 24.44 | 21.44 |
| EBIT 1 | -48.79 | 15.8 | 14 | 17.99 | 11.92 |
| Operating Margin | -10.15% | 2.73% | 2.47% | 2.68% | 1.54% |
| Earnings before Tax (EBT) 1 | -53 | 9.063 | 1.611 | 2.518 | -5.698 |
| Net income 1 | -53.62 | -3.159 | -8.149 | -14.36 | -15.43 |
| Net margin | -11.15% | -0.55% | -1.44% | -2.14% | -1.99% |
| EPS 2 | -0.3232 | -0.0190 | -0.0491 | -0.0857 | -0.0914 |
| Free Cash Flow 1 | 8.176 | -5.974 | -37.22 | - | 7.755 |
| FCF margin | 1.7% | -1.03% | -6.56% | - | 1% |
| FCF Conversion (EBITDA) | - | - | - | - | 36.17% |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 29/04/19 | 16/07/20 | 24/05/21 | 28/11/22 | 30/10/23 |
1HKD in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | 91.6 | 93.9 | 124 | 144 | 128 |
| Net Cash position 1 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -2.028 x | 4.592 x | 6.52 x | 5.882 x | 5.972 x |
| Free Cash Flow 1 | 8.18 | -5.97 | -37.2 | - | 7.75 |
| ROE (net income / shareholders' equity) | 138% | -22% | -4.02% | - | -121% |
| ROA (Net income/ Total Assets) | -20.7% | 6.12% | 4.8% | - | 3.04% |
| Assets 1 | 258.6 | -51.64 | -169.7 | - | -507.8 |
| Book Value Per Share 2 | -0.2900 | -0.3100 | -0.2300 | -0.2200 | -0.2000 |
| Cash Flow per Share 2 | 0.0300 | 0.0300 | 0.0300 | 0.0400 | 0.0400 |
| Capex 1 | 6.56 | 13 | 12.5 | 11.2 | 28.2 |
| Capex / Sales | 1.36% | 2.24% | 2.21% | 1.67% | 3.64% |
| Announcement Date | 29/04/19 | 16/07/20 | 24/05/21 | 28/11/22 | 30/10/23 |
1HKD in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -23.61% | 2.5M | |
| +12.75% | 27.8B | |
| +0.58% | 4.41B | |
| +11.90% | 1.74B | |
| -15.01% | 630M | |
| -3.50% | 540M | |
| -14.25% | 110M | |
| -11.41% | 52.86M |
- Stock Market
- Equities
- 660 Stock
- Financials Wai Chun Bio-Technology Limited